How much profit has NANO MRNA Co made this year?
NANO MRNA Co has made -780 M JPY this year.
NANO MRNA Co Net Income 2024
NANO MRNA Co Net Income
-780 M JPY
Ticker
4571.T
ISIN
JP3651120002
WKN
A0NCX4
In 2024, NANO MRNA Co's profit amounted to -780 M JPY, a -40.5% increase from the -1.31 B JPY profit recorded in the previous year.
The NANO MRNA Co Net Income history
| YEAR | NET INCOME (undefined JPY) |
|---|---|
| 2024 | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
| 2010 | - |
| 2009 | - |
| 2008 | - |
| 2007 | - |
| 2006 | - |
| 2005 | - |
NANO MRNA Co Revenue, EBIT, Net Income JP3651120002 · A0NCX4
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into NANO MRNA Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by NANO MRNA Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects NANO MRNA Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of NANO MRNA Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into NANO MRNA Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing NANO MRNA Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on NANO MRNA Co’s growth potential.
NANO MRNA Co Revenue, EBIT and net profit per share
| Date | NANO MRNA Co Revenue | NANO MRNA Co EBIT | NANO MRNA Co Net Income |
|---|---|---|---|
| 2024 | 135.51 M undefined | -864.42 M undefined | -780 M undefined |
| 2023 | 202.19 M undefined | -1.25 B undefined | -1.31 B undefined |
| 2022 | 264.03 M undefined | -2.06 B undefined | -1.88 B undefined |
| 2021 | 313.26 M undefined | -1.3 B undefined | -2.84 B undefined |
| 2020 | 552.97 M undefined | -1.11 B undefined | -2.01 B undefined |
| 2019 | 496.73 M undefined | -1.8 B undefined | -1.81 B undefined |
| 2018 | 259.1 M undefined | -5.35 B undefined | -5.42 B undefined |
| 2017 | 218.69 M undefined | -2.71 B undefined | -2.68 B undefined |
| 2016 | 243.34 M undefined | -2.08 B undefined | -2.54 B undefined |
| 2015 | 675.8 M undefined | -1.11 B undefined | -207.16 M undefined |
| 2014 | 472.2 M undefined | -1.12 B undefined | -1.11 B undefined |
| 2013 | 373.8 M undefined | -526.8 M undefined | -484.4 M undefined |
| 2012 | 346.3 M undefined | -333.5 M undefined | -398 M undefined |
| 2011 | 84.3 M undefined | -519.9 M undefined | -555.2 M undefined |
| 2010 | 117.8 M undefined | -492.7 M undefined | -494.8 M undefined |
| 2009 | 353.6 M undefined | -531.8 M undefined | -524.5 M undefined |
| 2008 | 262.7 M undefined | -452.5 M undefined | -494 M undefined |
| 2007 | 103.4 M undefined | -717.3 M undefined | -729.4 M undefined |
| 2006 | 107.9 M undefined | -801.6 M undefined | -974.3 M undefined |
| 2005 | 113.4 M undefined | -502.9 M undefined | -509.5 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 113.4 M JPY | -502.9 M JPY | -509.5 M JPY |
| 2006 | 107.9 M JPY | -801.6 M JPY | -974.3 M JPY |
| 2007 | 103.4 M JPY | -717.3 M JPY | -729.4 M JPY |
| 2008 | 262.7 M JPY | -452.5 M JPY | -494 M JPY |
| 2009 | 353.6 M JPY | -531.8 M JPY | -524.5 M JPY |
| 2010 | 117.8 M JPY | -492.7 M JPY | -494.8 M JPY |
| 2011 | 84.3 M JPY | -519.9 M JPY | -555.2 M JPY |
| 2012 | 346.3 M JPY | -333.5 M JPY | -398 M JPY |
| 2013 | 373.8 M JPY | -526.8 M JPY | -484.4 M JPY |
| 2014 | 472.2 M JPY | -1.12 B JPY | -1.11 B JPY |
| 2015 | 675.8 M JPY | -1.11 B JPY | -207.16 M JPY |
| 2016 | 243.34 M JPY | -2.08 B JPY | -2.54 B JPY |
| 2017 | 218.69 M JPY | -2.71 B JPY | -2.68 B JPY |
| 2018 | 259.1 M JPY | -5.35 B JPY | -5.42 B JPY |
| 2019 | 496.73 M JPY | -1.8 B JPY | -1.81 B JPY |
| 2020 | 552.97 M JPY | -1.11 B JPY | -2.01 B JPY |
| 2021 | 313.26 M JPY | -1.3 B JPY | -2.84 B JPY |
| 2022 | 264.03 M JPY | -2.06 B JPY | -1.88 B JPY |
| 2023 | 202.19 M JPY | -1.25 B JPY | -1.31 B JPY |
| 2024 | 135.51 M JPY | -864.42 M JPY | -780 M JPY |
NANO MRNA Co stock margins JP3651120002 · A0NCX4
The NANO MRNA Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of NANO MRNA Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for NANO MRNA Co.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the NANO MRNA Co's sales revenue. A higher gross margin percentage indicates that the NANO MRNA Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the NANO MRNA Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the NANO MRNA Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the NANO MRNA Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the NANO MRNA Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the NANO MRNA Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
NANO MRNA Co Margin History
| NANO MRNA Co Gross margin | NANO MRNA Co Profit margin | NANO MRNA Co EBIT margin | NANO MRNA Co Profit margin |
|---|---|---|---|
| 2024 | 81.88 % | -637.91 % | -575.61 % |
| 2023 | 78.94 % | -616.26 % | -648.39 % |
| 2022 | 84.36 % | -780.62 % | -712.67 % |
| 2021 | 87.75 % | -415.91 % | -905.24 % |
| 2020 | 85.9 % | -199.97 % | -363.43 % |
| 2019 | 83.92 % | -362.83 % | -364.08 % |
| 2018 | 73.81 % | -2,065.42 % | -2,090.65 % |
| 2017 | 72.09 % | -1,240.19 % | -1,223.65 % |
| 2016 | 87.01 % | -855.86 % | -1,042.62 % |
| 2015 | 68.65 % | -163.99 % | -30.65 % |
| 2014 | 61.41 % | -237.84 % | -235.85 % |
| 2013 | 26.99 % | -140.93 % | -129.59 % |
| 2012 | 63.9 % | -96.3 % | -114.93 % |
| 2011 | 39.38 % | -616.73 % | -658.6 % |
| 2010 | 39.81 % | -418.25 % | -420.03 % |
| 2009 | 30.06 % | -150.4 % | -148.33 % |
| 2008 | 74 % | -172.25 % | -188.05 % |
| 2007 | 11.32 % | -693.71 % | -705.42 % |
| 2006 | 0.37 % | -742.91 % | -902.97 % |
| 2005 | 47.8 % | -443.47 % | -449.29 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | 47.8 % | -443.47 % | -449.29 % |
| 2006 | 0.37 % | -742.91 % | -902.97 % |
| 2007 | 11.32 % | -693.71 % | -705.42 % |
| 2008 | 74 % | -172.25 % | -188.05 % |
| 2009 | 30.06 % | -150.4 % | -148.33 % |
| 2010 | 39.81 % | -418.25 % | -420.03 % |
| 2011 | 39.38 % | -616.73 % | -658.6 % |
| 2012 | 63.9 % | -96.3 % | -114.93 % |
| 2013 | 26.99 % | -140.93 % | -129.59 % |
| 2014 | 61.41 % | -237.84 % | -235.85 % |
| 2015 | 68.65 % | -163.99 % | -30.65 % |
| 2016 | 87.01 % | -855.86 % | -1,042.62 % |
| 2017 | 72.09 % | -1,240.19 % | -1,223.65 % |
| 2018 | 73.81 % | -2,065.42 % | -2,090.65 % |
| 2019 | 83.92 % | -362.83 % | -364.08 % |
| 2020 | 85.9 % | -199.97 % | -363.43 % |
| 2021 | 87.75 % | -415.91 % | -905.24 % |
| 2022 | 84.36 % | -780.62 % | -712.67 % |
| 2023 | 78.94 % | -616.26 % | -648.39 % |
| 2024 | 81.88 % | -637.91 % | -575.61 % |
NANO MRNA Co Aktienanalyse
What does NANO MRNA Co do?
NANO MRNA Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding NANO MRNA Co's Profit Margins
The profit margins of NANO MRNA Co represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of NANO MRNA Co's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating NANO MRNA Co's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
NANO MRNA Co's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When NANO MRNA Co’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about NANO MRNA Co stock
How has the profit developed compared to last year?
The profit has increased by -40.5% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does NANO MRNA Co publish its earnings?
NANO MRNA Co publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of NANO MRNA Co?
The profits of NANO MRNA Co are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of NANO MRNA Co?
You can learn more about the earnings of NANO MRNA Co by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does NANO MRNA Co pay?
Over the past 12 months, NANO MRNA Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, NANO MRNA Co is expected to pay a dividend of 0 JPY.
What is the dividend yield of NANO MRNA Co?
The current dividend yield of NANO MRNA Co is .
When does NANO MRNA Co pay dividends?
NANO MRNA Co pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of NANO MRNA Co?
NANO MRNA Co paid dividends every year for the past 0 years.
What is the dividend of NANO MRNA Co?
For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.
In which sector is NANO MRNA Co located?
NANO MRNA Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von NANO MRNA Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of NANO MRNA Co from 9/10/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
When did NANO MRNA Co pay the last dividend?
The last dividend was paid out on 9/10/2024.
What was the dividend of NANO MRNA Co in the year 2023?
In the year 2023, NANO MRNA Co distributed 0 JPY as dividends.
In which currency does NANO MRNA Co pay out the dividend?
The dividends of NANO MRNA Co are distributed in JPY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von NANO MRNA Co
Our stock analysis for NANO MRNA Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NANO MRNA Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- NANO MRNA Co Revenue
- NANO MRNA Co Net Income
- NANO MRNA Co P/E
- NANO MRNA Co P/S
- NANO MRNA Co EBIT
- NANO MRNA Co Dividend
- NANO MRNA Co Stocks
- NANO MRNA Co Market capitalization
- NANO MRNA Co Debt
- NANO MRNA Co Liabilities
- NANO MRNA Co Equity
- NANO MRNA Co AAQS
- NANO MRNA Co Employees
- NANO MRNA Co ROE
- NANO MRNA Co ROA
- NANO MRNA Co ROCE